Compare PGEN & IPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGEN | IPI |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 471.8M |
| IPO Year | 2013 | 2007 |
| Metric | PGEN | IPI |
|---|---|---|
| Price | $4.38 | $38.85 |
| Analyst Decision | Buy | Strong Sell |
| Analyst Count | 5 | 1 |
| Target Price | $8.33 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 3.3M | 195.2K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 105.14 |
| EPS | N/A | ★ 0.56 |
| Revenue | $230,981,000.00 | ★ $298,328,000.00 |
| Revenue This Year | $1,115.92 | $5.01 |
| Revenue Next Year | $81.04 | N/A |
| P/E Ratio | ★ N/A | $70.50 |
| Revenue Growth | N/A | ★ 17.13 |
| 52 Week Low | $1.28 | $22.55 |
| 52 Week High | $5.47 | $50.34 |
| Indicator | PGEN | IPI |
|---|---|---|
| Relative Strength Index (RSI) | 55.30 | 45.70 |
| Support Level | $3.96 | $36.20 |
| Resistance Level | $4.40 | $48.71 |
| Average True Range (ATR) | 0.27 | 2.42 |
| MACD | 0.01 | -0.37 |
| Stochastic Oscillator | 46.74 | 16.59 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
Intrepid Potash Inc produces and sells potash and potash byproducts in three main product segments: Potash, Trio, and Oilfield Solutions. The Potash segment produces and sells potash to the agricultural industry as a fertilizer input, the industrial market as a component of oil and gas drilling fluid, and the animal feed market as a nutrient supplement. The Trio segment produces and sells specialty fertilizer that consists of potassium, sulfate, and magnesium and is mined from langbeinite ore. The oilfield solutions segment offers water, high-speed potassium chloride mixing services, saltwater disposal services, and trucking services. The vast majority of revenue is generated in the United States, where the firm's production facilities are located.